Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Circ Cardiovasc Imaging. 2018 Jun;11(6):e007394. doi: 10.1161/CIRCIMAGING.117.007394

Table 3.

Changes in TBRmax open label extension

Mean (p-value1)

Global change baseline compared to end of open label extension
 Difference −0.08 (0.002)
 % change (95% CI) −3.80% (−6.40%, −1.19%) (0.005)

Global change start of adalimumab compared to end of open label extension
 Difference −0.02 (0.538)
 % change 0.02% (−2.85%, 2.90%) (0.987)
1

One sample t-test

(statistically significant findings bolded)